Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which ...
Masimo Corp. is sponsoring a new clinical study titled “Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations.” The goal is to confirm ...
NEUCHATEL, Switzerland--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced the CE marking of the Rad-G™ with Temperature, a rugged handheld device that provides clinically proven SET® pulse ...
The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility Study Showed No Clinically Significant Bias Between Patients with Light ...
When a patient is receiving supplemental oxygen during surgery, there’s a risk that they’ll develop hyperoxia, where their arterial blood becomes oxygenated above normal levels, potentially leading to ...
More than a decade into their partnership, Masimo and GE HealthCare are still finding new ways to combine their respective patient monitoring technologies. In the latest expansion of their ...
Universal Surveillance Monitoring with Masimo SET ® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also Projected to Yield Significant Cost ...
In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones The INSPIRE Trial Prospectively Assesses Pulse ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results